EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Sodium-Glucose Cotransporter-2 Inhibitor Enhances Hepatic Gluconeogenesis and Reduces Lipid Accumulation via AMPK-SIRT1 Activation and Autophagy Induction

Si Woo Lee, Hyunki Park, Minyoung Lee, Hyangkyu Lee, Eun Seok Kang

Endocrinology and Metabolism · 2025

DOI: 10.3803/enm.2024.2223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology and Metabolism, 2025. Verfasst von Si Woo Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medicine, Yonsei University, Seoul, Korea. Hauptthemen laut MEDLINE: Gluconeogenesis, Sirtuin 1, Sodium-Glucose Transporter 2 Inhibitors, Autophagy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium-glucose cotransporter type 2 (SGLT2) inhibitors, such as dapagliflozin, are primarily used to lower glucose in type 2 diabetes. Recent studies suggest broader metabolic effects, particularly in the liver. This study explores the molecular mechanisms by which dapagliflozin influences hepatic glucose and lipid metabolism, hypothesizing that it activates the 5’-adenosine monophosphate-activated protein kinase (AMPK)-sirtuin 1 (Sirt1) pathway to promote gluconeogenesis and reduce lipid accumulation via autophagy.

Methods

HepG2 hepatocellular carcinoma cells were treated with dapagliflozin, and Western blotting, quantitative reverse transcription polymerase chain reaction, and fluorescence microscopy were used to assess gluconeogenic enzyme expression and autophagy. In vivo, mice with liver-specific autophagy related 7 (Atg7) deletion and those on a high-fat diet were used to evaluate glucose regulation, lipid metabolism, and autophagy.

Results

Dapagliflozin significantly increased expression of gluconeogenic enzymes like phosphoenolpyruvate carboxykinase (PEPCK) in HepG2 cells and enhanced autophagic flux, evidenced by increased light chain 3B (LC3B)-II levels and autophagosome formation. AMPK-Sirt1 activation was confirmed as the underlying mechanism. Additionally, dapagliflozin reduced fatty acid synthesis by suppressing enzymes such as acetyl-CoA carboxylase and fatty acid synthase, while promoting fatty acid degradation via carnitine palmitoyltransferase 1α (CPT1α) upregulation. In high-fat diet mice, dapagliflozin increased hepatic gluconeogenesis and reduced lipid accumulation, though serum cholesterol and triglyceride levels were unaffected.

Conclusion

Dapagliflozin enhances hepatic gluconeogenesis and reduces steatosis by activating the AMPK-Sirt1 pathway and promoting autophagy. These findings suggest that SGLT2 inhibitors could offer therapeutic benefits for managing hepatic lipid disorders, beyond glycemic control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GluconeogenesisSirtuin 1Sodium-Glucose Transporter 2 InhibitorsAutophagyLipid MetabolismLiverAMP-Activated Protein KinasesBenzhydryl CompoundsGlucosidesAnimalsHumansMiceHep G2 CellsMaleMice, Inbred C57BLDiet, High-Fat

Stichwörter der Autor:innen

DapagliflozinGluconeogenesisGlycemic controlNon-alcoholic fatty liver disease

Substanzen

Sirtuin 1Sodium-Glucose Transporter 2 InhibitorsAMP-Activated Protein KinasesBenzhydryl CompoundsdapagliflozinGlucosidesSirt1 protein, mouseSIRT1 protein, human

Autor:innen und Institutionen

  • Graduate School of Medicine, Yonsei University, Seoul, Korea.
  • Department of Clinical Nursing Science, Yonsei University College of Nursing, Seoul, Korea.
  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Severance Hospital Diabetes Center, Seoul, Korea.
  • Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science and ICT
  • Korea Health Industry Development Institute
  • Ministry of Health and Welfare

Zitieren

APA

Lee, S. W., Park, H., Lee, M., Lee, H., & Kang, E. S. (2025). Sodium-Glucose Cotransporter-2 Inhibitor Enhances Hepatic Gluconeogenesis and Reduces Lipid Accumulation via AMPK-SIRT1 Activation and Autophagy Induction. Endocrinology and Metabolism. https://doi.org/10.3803/enm.2024.2223

Vancouver

Lee SW, Park H, Lee M, Lee H, Kang ES. Sodium-Glucose Cotransporter-2 Inhibitor Enhances Hepatic Gluconeogenesis and Reduces Lipid Accumulation via AMPK-SIRT1 Activation and Autophagy Induction. Endocrinology and Metabolism. 2025. doi:10.3803/enm.2024.2223

BibTeX
@article{Lee2025,
  author = {Lee, Si Woo and Park, Hyunki and Lee, Minyoung and Lee, Hyangkyu and Kang, Eun Seok},
  title = {Sodium-Glucose Cotransporter-2 Inhibitor Enhances Hepatic Gluconeogenesis and Reduces Lipid Accumulation via AMPK-SIRT1 Activation and Autophagy Induction},
  journal = {Endocrinology and Metabolism},
  year = {2025},
  doi = {10.3803/enm.2024.2223}
}
Kostenlos starten →